Takeda Signs US$1.13 B Deal with Hutchmed for Colorectal Cancer Drug
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 2 (Table of Contents)
Published: 1 Feb-2023
DOI: 10.3833/pdr.v2023.i2.2761 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In an attempt to bolster its oncology pipeline, Takeda has paid Hutchmed US$400 M upfront and committed up to US$730 M more for the further development and commercialisation of fruquintinib outside of mainland China, Hong Kong and Macau...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS